Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in newborn macaques

• Published in: Nature medicine Vol. 22; no. 4; pp. 362 - 368
• Main Authors: Hessell, Ann J., Jaworski, J. Pablo, Epson, Erin, Matsuda, Kenta, Pandey, Shilpi, Kahl, Christoph, Reed, Jason, Sutton, William F., Hammond, Katherine B., Cheever, Tracy A., Barnette, Philip T., Legasse, Alfred W., Planer, Shannon, Stanton, Jeffrey J., Pegu, Amarendra, Chen, Xuejun, Wang, Keyun, Siess, Don, Burke, David, Park, Byung S., Axthelm, Michael K., Lewis, Anne, Hirsch, Vanessa M., Graham, Barney S., Mascola, John R., Sacha, Jonah B., Haigwood, Nancy L.
• Format: Journal Article
• Language: English
• Published: 21.03.2016
• ISSN: 1078-8956; 1546-170X
• DOI: 10.1038/nm.4063

Prevention of mother to child transmission (MTCT) of HIV remains a major objective where antenatal care is not readily accessible. We tested anti-HIV-1 human neutralizing monoclonal antibodies (NmAb) as post-exposure therapy in an infant macaque model for intrapartum MTCT. One-month-old rhesus macaques were inoculated orally with SHIV SF162P3 . On days 1, 4, 7, and 10 after virus exposure, we injected animals subcutaneously with NmAbs and quantified systemic distribution of NmAbs in multiple tissues within 24 h following administration. Replicating virus was found in multiple tissues by day 1 in animals without treatment. All NmAb-treated macaques were free of virus in blood and tissues at 6 months post-exposure. We detected no anti-SHIV T cell responses in blood or tissues at necropsy, and no virus emerged following CD8 + T cell depletion. These results suggest early passive immunotherapy can eliminate early viral foci and thereby prevent the establishment of viral reservoirs.